In a retrospective study of 71 patients with PDAC associated with BRCA1/2, it was observed that those with unresectable pancreatic cancer treated with platinum-based agents had significantly longer overall survival (OS) compared to those who received non-platinum agents (22 vs. 9 months, p = 0.039) [14]. The gene discussed is BRCA1; the disease is familial pancreatic carcinoma.